Inhibition of tumor relapse by syngeneic anti–third-party Tcm after syngeneic BMT. Lethally irradiated (8Gy TBI) BALB/c mice (H-2^d) received an intravenous transplant of 3 × 10⁶ syngeneic T-depleted BM cells (BALB/c nude [H-2^d]) in the presence or absence of 5 × 10³A20-luc lymphoma cells (day 0). On the following day, mice were intravenously injected with 10 × 10⁶ (n = 7) or 2 × 10⁷ (n = 5) BALB/c-derived anti–third-party Tcm or left untreated (A20 only) (n = 7). (A) Tumor growth was monitored by BLI from day 14 at weekly intervals. (B) Survival curves of the animals from the various treatment groups are shown.